The expression of SMARCA4 is not altered after dabrafenib or vemurafenib treatment in melanoma patients (Figure 3D) and is highly increased in proliferative melanoma and ki67 positive (>30%) melanoma (Figure 3 E). Here, SMARCA4 is linked to melanoma.